SR2211
Based on 1 publication(s) in Google Scholar
SR2211 is a potent, selective synthetic RORγ modulator and functions as an inverse agonist, with a Ki of 105 nM and an IC50 of ~320 nM.
For research use only. We do not sell to patients.
- Purity: 98.90%
- CAS No.: 1359164-11-6
- Formula: C26H24F7N3O
- Molecular Weight:527.48
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) SR2211
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CWR22R | IC50 |
10.13 μM
Compound: 1; SR2211
|
Antiproliferative activity against human 22Rv1 cells assessed as cell viability incubated for 96 hrs by Cell-Titer Glo assay
Antiproliferative activity against human 22Rv1 cells assessed as cell viability incubated for 96 hrs by Cell-Titer Glo assay
|
[PMID: 34121397] |
| CWR22R | IC50 |
6.42 μM
Compound: 2; SR2211
|
Antiproliferative activity against human 22Rv1 cells measured after 96 hrs by celltiter-glo assay
Antiproliferative activity against human 22Rv1 cells measured after 96 hrs by celltiter-glo assay
|
[PMID: 30964293] |
| DU-145 | IC50 |
45.69 μM
Compound: 2; SR2211
|
Antiproliferative activity against human DU145 cells measured after 72 hrs by celltiter-glo assay
Antiproliferative activity against human DU145 cells measured after 72 hrs by celltiter-glo assay
|
[PMID: 30964293] |
| HEK293 | EC50 |
320 nM
Compound: 13, SR2211
|
Agonist activity at RoRc-LBD (unknown origin) expressed in HEK293 cells assessed as transcriptional activity by GAL4 reporter assay
Agonist activity at RoRc-LBD (unknown origin) expressed in HEK293 cells assessed as transcriptional activity by GAL4 reporter assay
|
[PMID: 24502334] |
| HEK-293T | IC50 |
0.11 μM
Compound: 2; SR2211
|
Inhibition of Gal4-RORgamma-LBD (180 to 507 residues) (unknown origin) expressed in HEK293T cells after 24 hrs by dual-luciferase reporter assay
Inhibition of Gal4-RORgamma-LBD (180 to 507 residues) (unknown origin) expressed in HEK293T cells after 24 hrs by dual-luciferase reporter assay
|
[PMID: 27043267] |
| HEK-293T | IC50 |
320 nM
Compound: SR2211
|
Inhibition of GAL4-fused ROR gamma (unknown origin) expressed in HEK293T cells assessed as suppression of transcriptional activity after 20 hrs
Inhibition of GAL4-fused ROR gamma (unknown origin) expressed in HEK293T cells assessed as suppression of transcriptional activity after 20 hrs
|
10.1039/C3MD00005B |
| HepG2 | IC50 |
150 nM
Compound: 13, SR2211
|
Displacement of [3H]T0901317 from human RoRc expressed in HepG2 cells by scintillation proximity binding assay
Displacement of [3H]T0901317 from human RoRc expressed in HepG2 cells by scintillation proximity binding assay
|
[PMID: 24502334] |
| LNCaP | IC50 |
5.38 μM
Compound: 1; SR2211
|
Antiproliferative activity against human LNCaP cells assessed as cell viability incubated for 96 hrs by Cell-Titer Glo assay
Antiproliferative activity against human LNCaP cells assessed as cell viability incubated for 96 hrs by Cell-Titer Glo assay
|
[PMID: 34121397] |
| LNCaP | IC50 |
6.79 μM
Compound: 2; SR2211
|
Antiproliferative activity against human LNCAP cells measured after 96 hrs by celltiter-glo assay
Antiproliferative activity against human LNCAP cells measured after 96 hrs by celltiter-glo assay
|
[PMID: 30964293] |
| LNCaP C4-2B | IC50 |
10.06 μM
Compound: 2; SR2211
|
Antiproliferative activity against human C4-2B cells measured after 96 hrs by celltiter-glo assay
Antiproliferative activity against human C4-2B cells measured after 96 hrs by celltiter-glo assay
|
[PMID: 30964293] |
| LNCaP C4-2B | IC50 |
5.38 μM
Compound: 1; SR2211
|
Antiproliferative activity against human LNCaP C4-2B cells assessed as cell viability incubated for 96 hrs by Cell-Titer Glo assay
Antiproliferative activity against human LNCaP C4-2B cells assessed as cell viability incubated for 96 hrs by Cell-Titer Glo assay
|
[PMID: 34121397] |
| PC-3 | IC50 |
24.82 μM
Compound: 2; SR2211
|
Antiproliferative activity against human PC3 cells measured after 72 hrs by celltiter-glo assay
Antiproliferative activity against human PC3 cells measured after 72 hrs by celltiter-glo assay
|
[PMID: 30964293] |
The treatment of EL4 with SR2211 represses the IL-17 gene expression. Similarly, the expression of IL-23 receptor (Il23r) is significantly inhibited by SR2211. Treatment of EL-4 cells with SR2211 results in significant inhibition of IL-17 intracellular staining as compared to vehicle treated cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1359164-11-6
-
Appearance Solid
-
Molecular Weight 527.48
-
Formula C26H24F7N3O
-
Color Off-white to light brown
-
SMILES
FC1=C(C2=CC=C(CN3CCN(CC4=CC=NC=C4)CC3)C=C2)C=CC(C(C(F)(F)F)(O)C(F)(F)F)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Am J Pathol
2025 Sep 30:S0002-9440(25)00363-3. PMID: 41038274
Solvent & Solubility
DMSO : 100 mg/mL (189.58 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kumar N, et al. Identification of SR2211: a potent synthetic RORγ-selective modulator. ACS Chem Biol. 2012 Apr 20;7(4):672-7. [Content Brief]
[2]. Song Y, et al. Identification of N-phenyl-2-(N-phenylphenylsulfonamido)acetamides as new RORγ inverse agonists: Virtual screening, structure-based optimization, and biological evaluation. Eur J Med Chem. 2016 Jun 30;116:13-26. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8958 mL | 9.4790 mL | 18.9581 mL | 47.3952 mL |
| 5 mM | 0.3792 mL | 1.8958 mL | 3.7916 mL | 9.4790 mL | |
| 10 mM | 0.1896 mL | 0.9479 mL | 1.8958 mL | 4.7395 mL | |
| 15 mM | 0.1264 mL | 0.6319 mL | 1.2639 mL | 3.1597 mL | |
| 20 mM | 0.0948 mL | 0.4740 mL | 0.9479 mL | 2.3698 mL | |
| 25 mM | 0.0758 mL | 0.3792 mL | 0.7583 mL | 1.8958 mL | |
| 30 mM | 0.0632 mL | 0.3160 mL | 0.6319 mL | 1.5798 mL | |
| 40 mM | 0.0474 mL | 0.2370 mL | 0.4740 mL | 1.1849 mL | |
| 50 mM | 0.0379 mL | 0.1896 mL | 0.3792 mL | 0.9479 mL | |
| 60 mM | 0.0316 mL | 0.1580 mL | 0.3160 mL | 0.7899 mL | |
| 80 mM | 0.0237 mL | 0.1185 mL | 0.2370 mL | 0.5924 mL | |
| 100 mM | 0.0190 mL | 0.0948 mL | 0.1896 mL | 0.4740 mL |